Literature DB >> 24461388

The diagnosis and classification of microscopic polyangiitis.

Cees G M Kallenberg1.   

Abstract

Microscopic Polyangiitis (MPA) is a small vessel vasculitis. The disease is defined by the 2012 revised Chapel Hill Consensus Conference Nomenclature of Vasculitides [1] as necrotizing vasculitis, with few or no immune deposits, predominantly affecting small vessels (i.e. capillaries, venules, or arterioles). Necrotizing arteritis involving small and medium arteries may be present. Necrotizing glomerulonephritis is very common. Pulmonary capillaritis often occurs. Granulomatous inflammation is absent. MPA belongs to the ANCA-associated vasculitides (AAV). ANCA in MPA are predominantly directed against myeloperoxidase (MPO-ANCA) but may, in a minority of patients, be directed against proteinase 3 (PR3-ANCA). Not all patients, however, have ANCA. Microscopic polyangiitis (MPA) belongs to the anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides. MPA is clinically characterized by small-vessel vasculitis primarily affecting the kidneys and the lungs but other organs may be involved as well. Renal involvement, which can be the only manifestation, is clinically apparent as rapidly progressive glomerulonephritis and histopathologically as pauci-immune necrotizing and crescentic glomerulonephritis. ANCA in MPA are mainly directed to myeloperoxidase (MPO-ANCA). Besides their diagnostic significance, MPO-ANCA appear pathogenic in MPA. Rituximab with steroids is at least as effective as cyclophosphamide with steroids for induction of remission.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ANCA-associated vasculitis; Anti-myeloperoxidase antibodies; Anti-neutrophil cytoplasmic autoantibodies; Microscopic polyangiitis; Myeloperoxidase (MPO); Necrotizing and crescentic glomerulonephritis

Mesh:

Substances:

Year:  2014        PMID: 24461388     DOI: 10.1016/j.jaut.2014.01.023

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  17 in total

1.  Diagnostic Scheming.

Authors:  Marlene Martin; Reza Sedighi Manesh; Mark C Henderson; Jeffrey M Critchfield
Journal:  J Gen Intern Med       Date:  2015-08-26       Impact factor: 5.128

2.  Microscopic polyangiitis with dermatomyositis.

Authors:  Erin M Bauer; Ernest Brahn
Journal:  Eur J Rheumatol       Date:  2017-08-29

3.  Mean platelet volume can estimate the current vasculitis activity of microscopic polyangiitis.

Authors:  Ho Jae Kim; Seung Min Jung; Jason Jungsik Song; Yong-Beom Park; Sang-Won Lee
Journal:  Rheumatol Int       Date:  2018-03-19       Impact factor: 2.631

Review 4.  Anti-neutrophil cytoplasmic antibodies and their clinical significance.

Authors:  Supaporn Suwanchote; Muanpetch Rachayon; Pongsawat Rodsaward; Jongkonnee Wongpiyabovorn; Tawatchai Deekajorndech; Helen L Wright; Steven W Edwards; Michael W Beresford; Pawinee Rerknimitr; Direkrit Chiewchengchol
Journal:  Clin Rheumatol       Date:  2018-03-10       Impact factor: 2.980

5.  Anti-neutrophil cytoplasmic antibody-negative microscopic polyangiitis: A case report and literature review.

Authors:  Ran Wang; Xiao-Chun Yang; Si-Jing Zhou; Geng-Yun Sun
Journal:  Exp Ther Med       Date:  2015-05-26       Impact factor: 2.447

6.  The level of urinary α1 microglobulin excretion is a useful marker of peritubular capillaritis in antineutrophil cytoplasmic antibody associated vasculitis.

Authors:  Naro Ohashi; Sayaka Ishigaki; Kazuto Kitajima; Naoko Tsuji; Shinsuke Isobe; Takamasa Iwakura; Masafumi Ono; Tomoyuki Fujikura; Takayuki Tsuji; Yukitoshi Sakao; Akihiko Kato; Hideo Yasuda
Journal:  Clin Exp Nephrol       Date:  2014-12-21       Impact factor: 2.801

Review 7.  ANCA-associated vasculitis with renal involvement.

Authors:  Valentina Binda; Gabriella Moroni; Piergiorgio Messa
Journal:  J Nephrol       Date:  2017-05-30       Impact factor: 3.902

8.  Rheumatoid factor false positivity in patients with ANCA-associated vasculitis not having medical conditions producing rheumatoid factor.

Authors:  Jae-Seung Moon; Diane Da-Hyun Lee; Yong-Beom Park; Sang-Won Lee
Journal:  Clin Rheumatol       Date:  2017-11-08       Impact factor: 2.980

Review 9.  The Bach Family of Transcription Factors: A Comprehensive Review.

Authors:  Yin Zhou; Haijing Wu; Ming Zhao; Christopher Chang; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 10.817

10.  The combined prevalence of classified rare rheumatic diseases is almost double that of ankylosing spondylitis.

Authors:  Judith Leyens; Tim Th A Bender; Martin Mücke; Christiane Stieber; Dmitrij Kravchenko; Christian Dernbach; Matthias F Seidel
Journal:  Orphanet J Rare Dis       Date:  2021-07-22       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.